Stockscreener 앱 받기
9.68
3.31%
0.31
시간 외 거래:
9.69
0.010
+0.10%
전일 마감가:
$9.37
열려 있는:
$9.28
하루 거래량:
452.82K
Relative Volume:
0.90
시가총액:
$336.34M
수익:
$2.07M
순이익/손실:
$-47.68M
주가수익비율:
-3.4326
EPS:
-2.82
순현금흐름:
$-31.31M
1주 성능:
+4.88%
1개월 성능:
+1.89%
6개월 성능:
-13.03%
1년 성능:
-17.97%
1일 변동 폭
$9.15
$9.695
1주일 범위
$8.84
$9.695
52주 변동 폭
$8.12
$18.23
Delcath Systems Inc Stock (DCTH) Company Profile
명칭
Delcath Systems Inc
전화
(518) 743-8892
주소
566 QUEENSBURY AVENUE, QUEENSBURY, NY
Compare DCTH vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DCTH
Delcath Systems Inc
|
9.68 | 325.57M | 2.07M | -47.68M | -31.31M | -2.82 |
|
ABT
Abbott Laboratories
|
110.25 | 192.10B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
345.78 | 137.25B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
88.97 | 115.41B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
69.63 | 103.81B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
85.09 | 49.82B | 6.07B | 1.06B | 1.34B | 1.8063 |
Delcath Systems Inc Stock (DCTH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-06-28 | 개시 | Craig Hallum | Buy |
| 2024-05-14 | 개시 | Stephens | Overweight |
| 2022-07-26 | 재개 | Canaccord Genuity | Buy |
| 2021-12-10 | 개시 | H.C. Wainwright | Buy |
| 2021-03-09 | 개시 | Canaccord Genuity | Buy |
| 2021-01-05 | 개시 | BTIG Research | Buy |
| 2020-06-01 | 개시 | Laidlaw | Buy |
모두보기
Delcath Systems Inc 주식(DCTH)의 최신 뉴스
Delcath Systems Charts Profitable Path Amid Heavy Investment - TipRanks
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Delcath Systems (DCTH) - The Globe and Mail
Can Delcath Systems Inc expand into new marketsQuarterly Earnings Report & Risk Managed Trade Strategies - baoquankhu1.vn
Insider Buying: Sandra Pennell Acquires Shares of Delcath Systems Inc (DCTH) - GuruFocus
Fundamentals Check: Is Delcath Systems Inc a strong candidate for buy and holdMarket Performance Report & Accurate Intraday Trading Signals - baoquankhu1.vn
Propel Bio Management LLC Buys 212,457 Shares of Delcath Systems, Inc. $DCTH - MarketBeat
Delcath Systems publishes results from CHOPIN trial in The Lancet Oncology - Yahoo Finance
HC Wainwright Lowers Earnings Estimates for Delcath Systems - MarketBeat
Delcath announces publication of liver cancer treatment trial - Investing.com
Delcath announces publication of liver cancer treatment trial By Investing.com - Investing.com Canada
Delcath Highlights CHOPIN Phase 2 Results in Uveal Melanoma - TipRanks
Insider Buying: Gerard Michel Acquires Additional Shares of Delc - GuruFocus
CHOPIN uveal melanoma trial data in Lancet boosts Delcath (Nasdaq: DCTH) - Stock Titan
[Form 4] DELCATH SYSTEMS, INC. Insider Trading Activity - Stock Titan
Delcath Systems announces publication of Chopin clinical trial results in The Lancet Oncology - marketscreener.com
Delcath Systems, Inc. (NASDAQ:DCTH) Q4 2025 Earnings Call Transcript - Insider Monkey
Delcath Systems Announces Publication Of Chopin Clinical Trial Results In The Lancet Oncology - TradingView
Liver-directed therapy plus immunotherapy extends survival in uveal melanoma - Stock Titan
FY2029 EPS Forecast for Delcath Systems Decreased by Analyst - MarketBeat
Delcath Systems Reports Record 2025 Results, Outlines 2026 Growth Plan - National Today
Delcath: Fundamentals Intact, Despite Share Price Weakness (NASDAQ:DCTH) - Seeking Alpha
Delcath Systems, Inc. (NASDAQ:DCTH) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Uveal Melanoma Treatment Market Set to Soar: Breakthrough - openPR.com
DCTH Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Precision Trading with Delcath Systems Inc. (DCTH) Risk Zones - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Baxter International (BAX), Nautilus Biotechnolgy (NAUT) and Delcath Systems (DCTH) - The Globe and Mail
Delcath Systems (NASDAQ:DCTH) Lowered to Hold Rating by Wall Street Zen - MarketBeat
Craig-Hallum cuts Delcath Systems stock price target on revenue guide - Investing.com Canada
Delcath Systems (DCTH) First Profitable Year Tests Lofty 115.7x P/E Narrative - simplywall.st
BTIG lowers Delcath Systems stock price target to $19 on guidance - Investing.com Australia
BTIG Maintains Buy on Delcath Systems (DCTH) Feb 2026, PT Cut to $19 - Meyka
Delcath Systems Inc (DCTH) Q4 2025 Earnings Call Highlights: Rec - GuruFocus
Delcath targets at least $100M revenue in 2026 while expanding to 40 treatment centers - MSN
Delcath Systems Q4 Earnings Call Highlights - MarketBeat
Earnings Call Summary | Delcath Systems(DCTH.US) Q4 2025 Earnings Conference - 富途牛牛
DCTH: BTIG Lowers Price Target, Maintains Buy Rating for Delcath Systems | DCTH Stock News - GuruFocus
BTIG Research Cuts Delcath Systems (NASDAQ:DCTH) Price Target to $19.00 - MarketBeat
Earnings call transcript: Delcath Systems Q4 2025 sees revenue beat, stock dips - Investing.com Nigeria
Clear Street lowers Delcath Systems stock price target on revised revenue outlook - Investing.com UK
Delcath Systems Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Delcath Systems, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Biliary Tract Cancer Market: Expanding Revenue Landscape to 2034 – DelveInsight | AstraZeneca, Taiho Oncology, Delcath Systems, TransThera Sciences (Nanjing), Basilea Pharma, Eisai, Merck - Barchart.com
Delcath (DCTH) Reports Strong Q4 Revenue and Anticipates Future Growth - GuruFocus
DCTH Forecasts Robust Gross Margin for Fiscal Year 2026 - GuruFocus
DCTH: Record revenue, strong growth, and CHOPIN data set stage for further expansion in 2026 - TradingView
Delcath Systems Reports Fourth Quarter and Full Year 2025 Results - BioSpace
DELCATH SYSTEMS, INC. SEC 10-K Report - TradingView
DELCATH SYSTEMS ($DCTH) Releases Q4 2025 Earnings - Quiver Quantitative
Delcath Systems, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Delcath Systems earnings beat by $0.03, revenue topped estimates - Investing.com UK
Delcath Systems (NASDAQ: DCTH) lifts 2025 revenue, sets 2026 guidance - Stock Titan
Delcath Systems Inc (DCTH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.21%
0.24%
자본화:
|
볼륨(24시간):